Comparison · NCT02701634-sae
ENTO vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ENTO vs Placebo: serious adverse events. Trial comparisons, record NCT02701634-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02701634-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.469 | 0.309 | 0.636 | wilson | |
| Risk in group 2 | 0.333 | 0.198 | 0.504 | wilson | |
| Risk difference, group 1 minus group 2 | 0.135 | -0.0985 | 0.35 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.766 | 2.58 | log | |
| Odds ratio, group 1 over group 2 | 1.76 | 0.647 | 4.81 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ENTO than on Placebo | 7.38 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ENTO | ENTO 400 mg or 200 mg tablet twice daily for 48 weeks in combination with systemic corticosteroids as first-line therapy | 15 | 32 | EG000 |
| Group 2 | Placebo | Placebo to match entospletinib tablets for 48 weeks in combination with systemic corticosteroids as first-line therapy | 11 | 33 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to the last dose date plus 30 days (average exposure: ENTO = 18 weeks; Placebo = 17 weeks)
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
- NCT number
- NCT02701634
- Phases
- PHASE2
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- ENTO, Placebo
- Lead sponsor
- Gilead Sciences
- Results first posted
- 2018-12-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02701634?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02701634-sae